Login / DE | EN Navigation Grünenthal Group The Grünenthal Group The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a €2 billion company. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation. Read more... New Chief Commercial Officer Grünenthal Group Mark Fladrich takes office as the new CCO as of September 1, 2017 The Grünenthal Group announces that Mark Fladrich has taken office as new Chief Commercial Officer (CCO). In his last appointment Mark Fladrich served as Area Vice President, Southern and Western Europe for AstraZeneca. His aspiration is to bring the Global Commercial functions closer to the markets and to foster the interface between Commercial and R&D. Read more... Company Products Innovation Patients Media Partnering Jobs & Career My Pain feels Like... You are here: Home Overview Company Corporate Executive Board Supervisory Board Facts & Figures Compliance Sustainability Social Responsibility Initiatives History Production Sites Affiliates worldwide Memberships Products Innovation Focus Areas Facts and Figures Innovation Capabilities Partnering & Collaborations Our Pipeline Patients Patient Summit Understanding Pain Definition of Pain Pain Management Grünenthal's Press Centre News Downloads Contact Partnering Our Partnering Model Areas of Interest Contact Jobs & Career Service Contact Grünenthal Worldwide America Europe Grünenthal 2021 © Imprint Privacy Statement Disclaimer General Terms and Conditions